Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease (vol 101, pg 801, 2019)

被引：30
|
作者：
Tabrizi, Sarah J.
Ghosh, Rhia
Leavitt, Blair R.
机构：
来源：
NEURON | 2019年 / 102卷 / 04期
基金：
英国医学研究理事会; 英国惠康基金;
关键词：
D O I：
10.1016/j.neuron.2019.05.001
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页码：899 / 899
页数：1
相关论文
共 50 条
  • [41] The roles of Huntingtin Associated Protein 40 in Huntingtin functions and Huntington's disease pathogenesis
    Xu, S.
    Li, G.
    Ye, X.
    Ye, L.
    Xu, Z.
    Stimming, E. Furr
    Zhang, S.
    MOVEMENT DISORDERS, 2020, 35 : S104 - S104
  • [42] Therapeutic strategies in Huntington's disease
    Alberch, J
    Canals, JM
    Pérez-Navarro, E
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (04) : 449 - 465
  • [43] Therapeutic strategies for Huntington's disease
    Estevez-Fraga, Carlos
    Flower, Michael D.
    Tabrizi, Sarah J.
    CURRENT OPINION IN NEUROLOGY, 2020, 33 (04) : 508 - 518
  • [44] Neuroprotection in Huntington's disease (vol 26, pg 223, 2003)
    Lahousen, T
    Bonelli, RM
    CLINICAL NEUROPHARMACOLOGY, 2003, 26 (06) : 330 - 330
  • [45] Dopamine and Huntington's disease (vol 15, pg 445, 2015)
    Schwab, L. C.
    Garas, S. N.
    Drouin-Ouellet, J.
    Mason, S. L.
    Stott, S. R.
    Barker, R. A.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (11) : 1367 - 1367
  • [46] Reversible Huntington's disease? (vol 352, pg 1520, 1998)
    Bonelli, RM
    Költringer, P
    Kenner, L
    Reisecker, F
    LANCET, 2003, 362 (9388): : 1000 - 1000
  • [47] One Decade Ago, One Decade Ahead in Huntington's Disease (vol 34, pg 1434, 2019)
    Wild, E. J.
    Tabrizi, S. J.
    MOVEMENT DISORDERS, 2020, 35 (01) : 199 - 199
  • [48] Clinical and biomarker characteristics of Huntington's Disease patients recently proposed for huntingtin-lowering clinical trial inclusion
    Parkin, G.
    Thomas, E.
    Snell, C.
    Smirnova, A.
    Hall, A.
    Bohall, L.
    Churchill, E.
    Corey-Bloom, J.
    MOVEMENT DISORDERS, 2022, 37 : S304 - S304
  • [49] Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients
    van Roon-Mom, Willeke M. C.
    Roos, Raymund A. C.
    de Bot, Susanne T.
    NUCLEIC ACID THERAPEUTICS, 2018, 28 (02) : 59 - 62
  • [50] Identification and Optimization of RNA-Splicing Modulators as Huntingtin Protein-Lowering Agents for the Treatment of Huntington's Disease
    Liu, Longbin
    Malagu, Karine
    Haughan, Alan F.
    Khetarpal, Vinod
    Stott, Andrew J.
    Esmieu, William
    Vater, Huw D.
    Webster, Stephen J.
    van de Poel, Amanda J.
    Clissold, Cole
    Cosgrove, Brett
    Sutton, Benjamin
    Spencer, Jonathan A.
    Breccia, Perla
    Gancia, Emanuela
    Bonomo, Silvia
    Ladduwahetty, Tammy
    Lazari, Ovadia
    Patel, Hiral
    Atton, Helen C.
    Clifton, Steve
    Mota, Daniel M.
    Magnani, Dario
    O'Neill, Amy
    Stebbeds, Marta
    Macabuag, Natsuko
    Todd, Daniel
    Herva, Maria E.
    Mitchell, Philip
    Visser, Mijke
    Compte Sancerni, Sara
    Grand Moursel, Laure
    da Silva, Marta
    Kritikou, Eva
    Heikkinen, Taneli T.
    Bolkvadze, Tamuna
    Fodale, Valentina
    Spadafora, Debora
    Daldin, Manuel
    Bresciani, Alberto
    Mangette, John E.
    Doherty, Elizabeth M.
    Lee, Matthew R.
    Herbst, Todd
    Monteagudo, Edith
    Macdonald, Douglas
    Plotnikov, Nikolay V.
    Chambers, Mark
    Mcallister, George
    Munoz-Sanjuan, Ignacio
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (18) : 13205 - 13246
12345